Following is a bing translation because my 4 quarters of French classes were over 20 years ago and couldn’t do as well.

Adeno carcinoma lung mutated kras.J\’ have already been twice Alimta.I would like to know if it will work again 3rd?You talk about Nexavar: a t it a marketing authorisation for the lung? (France)Otherwise what d\’ another!Thank you thousand times for your help.

Welcome to Grace. I’m sorry for the language barrier. I hope you can read english, have someone translate for you, or try a web based translator.

It seems you are saying,
You have adenocarcinoma with a KRAS mutation.
You have been treated with alimta twice and want to know if it will work again.
You want information about nexavar.
You want to know of other treatment options.

This is a link to the most recent information, a financial paper which is too often the first bearer of news from trials. Unfortunately there was no advantage found in overall survival with nexavar. http://www.marketwatch.com/story/phase-3-mission-trial-of-nexavar-sorafenib-in-patients-with-non-small-cell-lung-cancer-did-not-meet-primary-endpoint-of-improving-overall-survival-2012-05-22

This is a link to 2nd line treatment options for nsclc http://cancergrace.org/lung/2010/10/04/lung-cancer-faq-2nd-line-nsclc-option/ They incllude alimta, tarceva, and taxotere. however other drugs are used as well such as gemzar and navelbine.

Going back to alimta would depend on whether or not your cancer progressed through it. If it was stopped for other reasons like the need for a treatment break people have gone back to it and it’s been effective.

Please don’t be afraid to try your english here. You may find it is better understood than you think.

All the best,
Janine

Please let us know if you read english.

Bonsoir benquoi, et bienvenue a GRACE. Comme Janine a ecrit, on prefererait parler anglais si c’est possible.
So *to continue translating* – “the lesions reduced in size, but after a few months they returned.
I’m asking myself whether the cancer knows how to protect itself against Alimta, as happens with other agents?
Another question: my mutation is KRAS. Could I have the ALK rearrangement or are the two mutually exclusive? As EGFR and KRAS are mutually exclusive. What of crizotinib? Which works for ALK.”

benquoi, I think you are right about ALK and KRAS. They are usually mutually exclusive, although in rare cases they have been found together, as Dr Ross Camidge explains here:
http://pharmastrategyblog.com/2010/11/crizotinib-and-alk-rearrangements-in-lung-cancer-an-interview-with-dr-ross-camidge.html/
Au sujet de KRAS, vous avez cherche des essai cliniques en France? (Have you looked for clinical trials?)
http://www.clinicaltrials.gov/ct2/results?term=France+NSCLC+KRAS
Dr West vient de participer a une rencontre des specialistes a Chicago. Il s’interesse aux resultats d’un KRAS essai mondiale (docetaxel vs docetaxel/selumetinib):
http://cancergrace.org/lung/2012/05/19/my-top-5-notable-asco-2012-abstracts-in-metastatic-nsclc/
On attend son avis et ses nouvelles. Meilleurs voeux.